This interview with an EU-based KOL provides insights into current prescribing habits on- and off-label in WHO groups 1–5, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for pulmonary hypertension. Key assets highlighted include Adempas, Tyvaso, sotatercept, Opsumit, Tracleer, Letairis, Adcirca, Revatio, Opsynvi, Yutrepia, ralinepag, GB002, and Simdax. 

This interview was conducted on 8 August 2023. 

If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only). 

Biomedtracker's KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900.

For our disclosures, please read the Biomedtracker Research Standards.